Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (65)

Advertisement

Research Article Free access | 10.1172/JCI105709

Estradiol metabolism in cirrhosis

Barnett Zumoff, Jack Fishman, T. F. Gallagher, and Leon Hellman

Division of Neoplastic Medicine and the Institute for Steroid Research, Montefiore Hospital and Medical Center, New York

Find articles by Zumoff, B. in: PubMed | Google Scholar

Division of Neoplastic Medicine and the Institute for Steroid Research, Montefiore Hospital and Medical Center, New York

Find articles by Fishman, J. in: PubMed | Google Scholar

Division of Neoplastic Medicine and the Institute for Steroid Research, Montefiore Hospital and Medical Center, New York

Find articles by Gallagher, T. in: PubMed | Google Scholar

Division of Neoplastic Medicine and the Institute for Steroid Research, Montefiore Hospital and Medical Center, New York

Find articles by Hellman, L. in: PubMed | Google Scholar

Published January 1, 1968 - More info

Published in Volume 47, Issue 1 on January 1, 1968
J Clin Invest. 1968;47(1):20–25. https://doi.org/10.1172/JCI105709.
© 1968 The American Society for Clinical Investigation
Published January 1, 1968 - Version history
View PDF
Abstract

Abnormal estrogen metabolism has been found in cirrhosis after administration of intravenous tracers of estradiol-3H to 6 patients and 23 healthy controls. The major abnormalities observed involved estrogen metabolites other than the 3 “classic” ones, i.e., estrone (E1), estradiol (E2), and estriol (E3). Urinary recovery of radioactivity was regularly elevated in the patients, to an average of 71% of the dose compared to 51% in normals. This is considered to reflect the component of intrahepatic cholestasis in cirrhosis. The per cent dose recovered as urinary glucosiduronates (42%) was normal in cirrhotics in contrast to impaired glucuronidation of cortisol metabolites in this disease. E1 and E2 were present in normal amounts, and E3 was slightly elevated to 21% of the extract compared to 14% in controls. There were strikingly decreased excretion of 2-hydroxyestrone (3% compared with normal 20%) and 2-methoxyestrone (2% compared with 5%) and increased excretion of 16α-hydroxyestrone (12% compared with normal 6%). Thus cirrhosis, too, is characterized by the reciprocal relationship between decreased 2-hydroxylation and increased 16α-hydroxylation previously described in hypothyroidism and male breast cancer. However, unlike these latter, the increase of 16α-hydroxy metabolites was less than the decrease of 2-hydroxy metabolites. The data indicate clearcut impairment of 2-hydroxylation, suggestive impairment of 16α-hydroxylation, and a definite depression of the reaction 16α-hydroxyestrone→estriol, the latter finding so far unique to cirrhosis. Demonstration of abnormal peripheral metabolism of estrogen in cirrhosis provides a new approach to the origin of the hyperestrogenic syndrome in this disease.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 20
page 20
icon of scanned page 21
page 21
icon of scanned page 22
page 22
icon of scanned page 23
page 23
icon of scanned page 24
page 24
icon of scanned page 25
page 25
Version history
  • Version 1 (January 1, 1968): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (65)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts